These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases. Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948 [TBL] [Abstract][Full Text] [Related]
9. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072 [TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622 [TBL] [Abstract][Full Text] [Related]
11. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808 [TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Zhang GY; Ahmed N; Riley C; Oliva K; Barker G; Quinn MA; Rice GE Br J Cancer; 2005 Jan; 92(1):113-9. PubMed ID: 15583697 [TBL] [Abstract][Full Text] [Related]
13. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related]
14. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
15. [Expression of folate receptor alpha in ovarian epithelial tumors]. Shen DH; Xie JL; Zhang YL; Wang Y Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165 [TBL] [Abstract][Full Text] [Related]
16. p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Liao XY; Xue WC; Shen DH; Ngan HY; Siu MK; Cheung AN Histopathology; 2007 Oct; 51(4):477-83. PubMed ID: 17880529 [TBL] [Abstract][Full Text] [Related]
17. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential). Scully RE Bull Cancer; 1982; 69(3):228-38. PubMed ID: 6289947 [TBL] [Abstract][Full Text] [Related]
18. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
19. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study. Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376 [TBL] [Abstract][Full Text] [Related]
20. [In-vitro metaboli studies on normal human ovaries, benign and malignant ovarian tumors]. Hackl H Arch Gynakol; 1967; 204(4):167-77. PubMed ID: 5631017 [No Abstract] [Full Text] [Related] [Next] [New Search]